Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10;12(8):e060416.
doi: 10.1136/bmjopen-2021-060416.

COCOS trial: CO rticosteroids for CO VID-19-induced loss of S mell-protocol for a single-centred, double-blind, randomised, placebo-controlled trial

Emma J A Schepens  1   2 , Wilbert M Boek  3 , Sanne Boesveldt  4 , Inge Stegeman  5   2 , Robert J Stokroos  5   2 , Digna M A Kamalski  5   2
Affiliations

COCOS trial: CO rticosteroids for CO VID-19-induced loss of S mell-protocol for a single-centred, double-blind, randomised, placebo-controlled trial

Emma J A Schepens et al. BMJ Open. .

Abstract

Introduction: Hyposmia and anosmia are common in COVID-19. Most patients regain normal smell within 4 weeks, but severe loss of smell persists roughly in 20% after 2 months and may last up to a year or longer. These persistent smell disorders greatly influence daily life. It is hypothesised that COVID-19 induces inflammation around the olfactory nerve and in the olfactory pathway, leading to smell disorders. Corticosteroids might reduce this local inflammatory response and improve smell.

Methods and analysis: We will conduct a single-centre, randomised, placebo-controlled trial to determine the efficacy of a short high-dose treatment of oral prednisolone for persistent loss of smell after COVID-19 in the early phase. We will include 116 patients with persistent (>4 weeks) loss of smell within 12 weeks of COVID-19 diagnosis, based on a positive PCR/antigen test. One group receives 40 mg of prednisolone for 10 days and the other group receives matching placebo treatment. In addition, all patients will perform smell training for 12 weeks. The primary outcome is objective olfactory function measured by means of sniffin' sticks test. Secondary outcomes are objective gustatory function by means of taste strips test and subjective taste and smell ability, trigeminal sensations, quality of life and nasal symptoms, measured by three questionnaires. These outcomes will be measured at inclusion before treatment and 12 weeks later.

Ethics and dissemination: The Institutional Review Board of the University Medical Center Utrecht approved the research protocol (21-635/G-D, October 2021). The trial results will be shared in peer-reviewed medical journals and scientific conferences.

Trial registration number: NL9635. EUCTR2021-004021-71-NL.

Keywords: COVID-19; INFECTIOUS DISEASES; OTOLARYNGOLOGY.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Study flow chart. SST, sniffin’ sticks test; TDI-score, threshold, discrimination, identification score; TST, taste strips test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Parma V, Ohla K, Veldhuizen MG, et al. . More than Smell-COVID-19 is associated with severe impairment of smell, taste, and Chemesthesis. Chem Senses 2020;45:609–22. 10.1093/chemse/bjaa041 - DOI - PMC - PubMed
    1. Lechner M, Chandrasekharan D, Jumani K, et al. . Anosmia as a presenting symptom of SARS-CoV-2 infection in healthcare workers - A systematic review of the literature, case series, and recommendations for clinical assessment and management. Rhinology 2020;58:394–9. 10.4193/Rhin20.189 - DOI - PubMed
    1. Borsetto D, Hopkins C, Philips V, et al. . Self-Reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology 2020;58:430–6. 10.4193/Rhin20.185 - DOI - PubMed
    1. Spinato G, Fabbris C, Polesel J, et al. . Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA 2020;323:2089–90. 10.1001/jama.2020.6771 - DOI - PMC - PubMed
    1. Boscolo-Rizzo P, Polesel J, Spinato G, et al. . Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19. Rhinology 2020;58:524–5. 10.4193/Rhin20.263 - DOI - PubMed

Publication types